| Dr Barrie Ward | Chairman of the Board |
| Dr Chris Martin | Chief Executive Officer (CEO) |
| Prof David Thurston | Chief Scientific Officer (CSO) |
| Dr Chris Keightley | Non Executive Director |
| Dr Maria Dahl | Non Executive Director |
Dr Ward brings a tremendous wealth of leadership skills and experiences to Spirogen Ltd. He is currently Chairman of the Board of Directors of Onyvax Ltd. He has served as Chief Executive Officer of KuDOS Pharmaceuticals Ltd and Chief Executive Officer and Chairman of the Board of Directors of Virus Research Institute, Inc. Earlier in his career, Dr Ward worked in research for Glaxo Ltd., where he became Director of the Microbiology Division of Glaxo Research and Development Ltd.
Chris has over 20 years experience in the pharmaceutical and biotech sector. He is non-executive Chairman of Sciona, Inc. and was a founder of Paras Ltd. and Xenva Ltd. Chris is a Fellow of the Institution of Chemical Engineers and a Sainsbury Management Fellow (MBA, IMD 1989).
David Thurston is Professor of Anticancer Drug Discovery at the School of Pharmacy, University of London, where he is also Director of the CR-UK Protein-Protein Interactions Drug Discovery Research Group. He is a pharmacist by training, and has spent most of his career in academic research involved with the discovery, medicinal chemistry and development of anticancer agents. He began the programme of research in 1987 that led to the founding of Spirogen in 2001.
Professor Thurston has more than 110 publications in key chemistry, biochemical and medicinal chemistry journals, and has been a member of several national scientific committees including the Cancer Research UK New Agents Committee which oversees the acceptance of novel antitumor agents for development and clinical trial. In the regulatory area he has recently completed a period of membership of the Committee on Safety of Medicines (CSM), and also chaired its Chemistry, Pharmacy & Standards (CPS) Sub-Committee. To-date he has supervised over 50 postdoctoral research fellows and PhD students.
Dr Keightley is the founder and managing director of Cambridge Research BioVentures Ltd, an investment fund that provides early stage capital for biomedical and life science companies. The fund is backed by Research Corporation Technologies of Tucson Arizona, the world's largest and most successful independent technology transfer organization. He has an MA in physiology and a Ph.D in biochemistry from Cambridge University. Chris has 20 years of experience at a senior management level in the life sciences sector, having founded his own diagnostics company (IQ Bio Ltd.) which was sold to the Danish pharmaceuticals giant Novo. More recently, he was Director of Life Sciences at Cambridge Research & Innovation Ltd. (CRIL), where he was responsible for their life science investments. He is also a Director of a number of early stage biotechnology companies.
Astrid Maria Dahl is Vice-President Oncology Portfolio Management at IPSEN. Dr. Dahl has more than ten years of experience in the US and UK biotechnology and pharmaceutical industry following an initial career in research, working as a research fellow in immunology at Harvard Medical School in Boston. She worked from 2001 in business development in the San Francisco based biotechnology company Cell Genesys, prior to joining IPSEN's London office in 2004. At IPSEN she was responsible for oncology in the corporate business development team prior to moving on to head the entire oncology portfolio team in 2008. Dr. Dahl has a Ph.D in tumour immunology from the Imperial Cancer Research Fund/University College London and an MBA from the University of California at Berkeley.